Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A clinical review of sermorelin acetate FAERS safety signals, FDA adverse-event reporting patterns, post-market surveillance findings, and what the data means for prescribers and patients.
Read clinical reviewA complete regulatory history of sermorelin acetate, from its 1997 FDA approval through voluntary market withdrawal and current 503A compounding status, with clinical trial data and safety context.
Read clinical reviewA comprehensive review of sermorelin acetate label changes, FDA regulatory actions, compounding pharmacy status, and post-market safety data from 2020 through 2026.
Read clinical reviewA clinical review of sermorelin acetate's regulatory history, current compounding status, and the next-generation GHRH analogs and GH secretagogues in development that may reshape growth hormone therapy.
Read clinical reviewA detailed comparison of how the FDA and EMA have handled sermorelin acetate, from its original 1997 approval through withdrawal and current compounding status.
Read clinical review